CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Olanzapine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00035321
NCT00035321Phase 3Completed
CompareCT.gov

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features

Eli Lilly and Company·interventional·Posted May 3, 2002·Updated Jul 24, 2006

In Brief

A Phase 3 clinical trial evaluating Olanzapine and Fluoxetine for Major Depressive Disorder. Completed, across 33 sites in 2 countries.

Detailed Summary

The purposes of this study are to determine: * Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. * The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. * The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 3, 2002
Enrollment StartApr 1, 2002
Study CompletionJul 1, 2005
TodayJul 2, 2026
Posted 24.2 years ago

Interventions

Olanzapinedrug

Fluoxetinedrug